Neil Gross

Clinical trials

• Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

  Principal investigator · Suspended · Phase 3

  National Cancer Institute (NCI)

  2025–2031
• Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

  Principal investigator · Active not recruiting · Phase 2

  M.D. Anderson Cancer Center

  2018–2027
• Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell

  Principal investigator · Unknown

  M.D. Anderson Cancer Center

  2016–2021
• Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

  Principal investigator · Withdrawn · Phase 1, Phase 2

  OHSU Knight Cancer Institute

  2011–2013